Erik Abrahamson is a Senior Vice President with CBRE and has been involved in nearly $1 billion of transactions since joining CBRE. Erik was instrumental in CBRE’s expansion in Boulder, Colorado. Erik brings a technical background in engineering, commercial property development, acquisition and dispositions to his agency brokerage role.

Erik Abrahamson is a recognized as an expert in life science and office/flex real estate within in the Boulder / Northwest Denver commercial real estate community. He has been involved in some of the region’s largest Life Science transactions and his client list includes Beacon Capital Partners, Clarion Partners, TriTower Financial Group, Steelwave, Graham Street and other institutional level owners in the greater Boulder/Denver region. Significant transactions that Erik has worked on include Agilent Technologies Nucleic Acid-Based Therapeutics land purchase and plant development in Frederick, CO, a $185 million plant covering over 135,000 SF and Agilent Technologies purchase of 5555 Airport Blvd in Boulder, CO. In 2020 Erik was involved in one of Boulder’s largest transactions, TriTower’s renewal of Pfizer at 3200 Walnut in Boulder, CO, a 150,000 SF life science facility in the heart of Boulder. Erik has also been involved in life science transactions with Eli Lilly, Umoja Biophamra, Medtronic, SomaLogic, Colorado Therapeutics and Colibri Heart Valves to name a few.

Erik advises institutional clients in one of the nation’s most dynamic and accelerating markets, Boulder, Colorado. His knowledge and understanding of what drives the Boulder economy and what attracts tenants to Boulder makes Erik instrumental in his commercial real estate advising. Collectively, this expertise empowers his clients to effectively mitigate risk while leveraging all real estate opportunities in this evolving market.

Education
• University of Colorado, MS
• University of Wisconsin, BS